Purpose: Renal dysfunction remains a serious complication of coronary artery bypass grafting (CABG) surgery and is associated with increased mortality and morbidity. To date, a number of different strategies, including new pharmacologic agents, off-pump and cardiopulmonary bypass techniques have been used to avoid it, but none of them proves the excellent result. Methods: Between April 2009 to September 2011, 185 consecutive patients with multivessel coronary artery disease undergoing elective CABG were included the study. Iloprost was given with the onset of rewarming period at a dose of 1.25-2.5 ng/kg/min and it was ended together with the ending of CPB in 94 patients and remaining were in the control group. Creatinine clearance (CCr) and GFR were measured at the time of hospitalisation and on day first and fifth postoperatively. Serum potassium level was determined every 6 hours, during the first 24 hours postoperatively, and every 12 hours for the next 72 hours, and glomerular filtration rate was estimated. Results: There was no statistically significant difference in preoperative comorbidity. There were no significant differences in postoperative morbidity or mortality between either of the two groups that completed the study. However, urine output during the operation was significantly higher in the study group. An increase in creatine levels was more common in the control group. Development of a new CCr less than 50 ml/min was also significantly higher in the control group, postoperatively. Conclusion: Our study demonstrates that prophylactic intravenous iloprost administration after initiation of a rewarming period during CPB in patients undergoing CABG surgery is associated with improved renal function, compared with conventional treatment in wellhydrated patients. It also has a good safety profile and is generally well tolerated.
Introduction
Renal dysfunction remains a serious complication of coronary artery bypass grafting (CABG) surgery and associated with increased mortality and morbidity, especially if hemodialysis is required. [1] [2] [3] The incidence of acute renal failure (ARF) requiring renal replacement therapy is 3.53% in a review of Society of Thoracic Surgeons (STS) database. 4) To date, a number of different strategies, including new pharmacologic agents, off-pump and cardiopulmonary bypass techniques have been used to avoid it. Considering pharmacologic agents, a few medications have been used by now such as prostacyclin, nitroprussid, levosimendan, dexamethasone and n-acetylcysteine, 2, [5] [6] [7] [8] [9] [10] but none of them proves the excellent result for it. In this study, we sought to determine the renal effect of iloprost during the reperfusion period in patients undergoing CABG.
Materials and Methods
Between April 2009 to September 2011, a sum of 185 consecutive patients with multivessel coronary artery disease undergoing elective CABG were included in the study. All were informed with written patient consent after ethical committee approval. They were randomly allocated to either the control or iloprost group. They were eligible if they had any of following items: requiring at least two major coronary arteries, left ventricular ejection fraction (LVEF) <0.50 and estimated glomerular filtration rate (GFR) >30 ml/min supposing those patients are at risk of acute renal failure in spite of normal renal function as seen in literature. 1, 11, 12) Patients were excluded the study with any one of the following criteria: unstable angina pectoris, congestive heart failure, myocardial infarction in within the last week, renal failure with serum creatinine level >3 mg/dl, microalbuminurea, hepatic dysfunction, cachexia or morbid obesity, transient or permanent neurological stroke, concomitant major cardiac problems.
Renal function test
Serum creatinine (SCr) and GFR were measured at the time of hospitalisation and on day first and fifth postoperatively. Serum potassium level was determined every 6 hours during the first 24 hours postoperatively and every 12 hours for the next 72 hours. Urine was collected using an indwelling Foley catheter during surgery, 72 hours postoperatively, and it was measured every hour. GFR was estimated from the modification of diet in the renal disease equation for men as follows. Result of this equation was multiplied by a correction factor of 0,742 for women. Creatinine clerence (C Cr )was calculated using the Cockroft and Gault formula: 14) C Cr = (140 -age) × weight (kg) / (serum creatinine × 72 [× 0.85 for women])
Surgical technique and anesthesic management
Premedication was oral diazepam. Anesthesia was induced with fentanyl and pancuronium intravenously. Routine monitoring was completed after induction of anesthesia and included invasive arterial pressure, central venous pressure (CVP), central and peripheral temperatures and an indwelling bladder catheter. Surgical access to the heart was through a standard median sternotomy in all patients. Blood glucose levels, arterial blood gases and activated clotting time were monitored every hour.
Non-pulsatile CPB was used with a roller pumps and microporous hollow fiber membrane oxygenators (Dideco D903 Avant, Modena, Italy) primed with 1200 ml of lactated ringer solution. 5000 IU of heparin and 100 mmol of sodium bicarbonate were also added to the priming solution. Pump flow was 2.4-2.8 l/min/m 2 . Mild hypothermia (28°C-30°C) was used in all patients. During CPB, mean arterial pressure (MAP) was allowed to vary 50 to 60 mmHg. Alpha-stat pH management was employed. Intermittant cold-blood cardioplegia (1:4 blood to crystalloid) was delivered via the aortic root. Durations of operation, CPB and cross clamp were recorded.
Iloprost protocol
Iloprost was given with the onset of rewarming period at a dose of 1.25-2.5 ng/kg/min and it was ended together with the ending of CPB. Determining initial dose of iloprost, we considered literature showing low dose prostacyclin preserves renal function in bypass surgery. 8, 15) The dose was readjusted considering systemic blood pressure, keeping the mean blood pressure between 50 to 60 mmHg during this time. During rewarming, a 4°C-6°C difference between rectal and CPB perfusate temperature was maintained for all patients. Total amount of iloprost used for each patient was noticed.
Cardiac biomarkers
Venous blood samples were drawn just before and during CPB at 10th minutes. It also was drawn after release of the aortic clamp at 6th, 12th, 24th, 48th and 72nd hours. Concentrations of mass of isoenzyme MB of creatine kinase (CK-MB) and cardiac troponin I (cTnI) were determined at these times. The upper limit of normal was defined as 6.3 for CK-MB and 0.04 ng/ml for cTnI.
Patient follow-up
All patients were kept in the intensive care unit concerning hemodynamic parameters and urine output. In both groups, urine output was maintained at more than 0.5 ml/kg/h. Diuretics were used when necessary. Arterial blood gases, serum electrolytes, glucose, BUN, C Cr were obtained daily till to discharge. Routine postoperative medication for CABG was also given, such as betablockers, aspirin and statins. Nephrotoxic agents and dopamine were avoided. Dobutamin was used when an inotropic agent when required.
Statistical analysis
All statistical evaluations were done SPSS version 10.0 for Windows, and all tests were two-sided, with a significance level of p <0.05.
Results
Baseline characteristics of the patients are summarized in Table 1 . There was no statistically significant difference in preoperative comorbidity between the two groups, who completed the study. Additionally, both groups had similar EuroSCORES, extends of coronary revascularization, durations of CPB and aortic cross clamping and operative times. Five patients in the study group developed hypotension after beginning of iloprost infusion as perfusion pressure got lower than of 50 mmHg. Their arterial pressure recovered after concomitant infusion of dobutamine. Two patients also developed hypotension during rewarming and weaning in the cardiopulmonary bypass period, and they were also treated with a similar regime of infusion. Two patients died in control and study groups due to low cardiac output postoperatively and excluded the study.
Considering renal function, 65 patients had normal renal function. Other 95 patients had mild and remaining 25 ones had moderate renal dysfunction. In the three functional status, distribution of the patients in the groups was homogenous with a statistically insignificant difference (p >0.05) ( Table 1 ). The mean creatinine was 1.02 + 0.20 mg/dl on arrival. GFR and blood urea nitrogen levels are also similar between the groups (p >0.05) ( Table 1) .
Operation, cardiopulmonary bypass, cross-clamp times and other operation parameters were all similar between the groups (p >0.05), but urine output during the operation was significantly higher in the study group. It was also higher in cardiopulmonary bypass duration (p <0.05). Also, an increase in creatine levels was more common in the control group. Meanwhile, development of a new C Cr less than 50 ml/min was significantly higher in the control group postoperatively (p <0.05). There were no significant differences in postoperative morbidity or mortality (p >0.05) ( Table 2 ).
Discussion
ARF after CABG has a significant influence on postoperative morbidity and mortality. The benchmark study conducted by Chertow et al. 12) reported mortality of 63% at 30 days for those patients requiring hemodialysis compared with 4.3% for those without renal dysfunction. A more recent work by Mongano et al. 16 ) identified similar mortality rates among patients with postoperative renal failure. Several risk factors have been identified as independent predictors of ARF after cardiac surgery such as age, left ventricle ejection fraction less than 35%, increased preoperative serum creatinine, nonelective surgery, diabetes, prolonged CPB duration and low cardiac output. 1, 3, 12, 16, 17) CPB represents several risk factors on renal physiology including nonpulsatile perfusion, renal hypoperfusion, hypothermia and increased levels of circulating catecholamines, cytokines and free hemoglobin a result of hemolysis. [18] [19] [20] [21] To date, various studies have been done to avoid deleterious effect of cardiopulmonary bypass. Of them, offpump technique for coronary revascularization was popularized in early 1990s, which led to an investigation as to whether the avoidance of CPB altogether would minimize postoperative renal injury and/or insufficiency. Although some of the previous retrospective analyses demonstrate a significant renoprotective effect of the off-pump technique, some others have failed about it. 19, 22, 23) Above all, the literature contains many conflicting reports on the results of off-pump surgery. 24) Iloprost, a cytoprotective prostacyclin anolog, has been used in organ protection for various purpose. [5] [6] [7] 21) Of them, Sahsivar et al. 7) used iloprost in renal injury models in an experimental study. They have demonstrated that iloprost significantly decreased renal ischemia reperfusion injury in a rat model. Similarly, Mongera et al. 8) used low-dose prostacyclin in high risk patients during and after coronary bypass surgery, and they have showed that it preserves kidney function in them. Apart from them, in our clinical study, we used iloprost in patients with mostly normal renal function undergoing coronary bypass surgery with cardiopulmonary bypass, and we have shown that infusion of a prostacyclin analog provides better renal protection then the control group. However, because hypotension is also the principal, dose dependent side effects of iloprost, we closely monitored all serious hypotension events in this study. The decision to down titrate or discontinue iloprost because of drug-related side effects in this study was rare, and its incidence was not significantly different between the groups. Another potential area of concern in our study with regard to safety was the possibility of surgical bleeding resulting from the platelet-inhibition properties of iloprost. 21) However, iloprost at a dose of 1.25-2.5 ng/kg/min causes minor inhibition of ADP-induced platelet aggregation and has no effect on intrinsic coagulation system and postoperative drainage of bleeding. The antiplatelet effect of iloprost is short-lived, and iloprost is rapidly eliminated. 25, 26) Indeed, the results of bleeding requiring revision did not differ between the groups significantly in our study.
Although the protective effect of prostacyclin is considered to be primary result of its vasoditory action, a direct protective action on renal epithelial cells has also been shown in an in vitro model of hypoxia/reoxygenation-induced injury, in cultured rat proximal renal tubular cells 27) . Moreover, low dose prostacyclin (2 ng/kg.dk), started immediately before cardiac surgery, which was continued for a maximum of 48 hours, has been shown to preserve renal function in high risk patients with impaired left ventricular fraction undergoing surgical revascularization.
8)

Conclusion
Our study demonstrates that prophylactic intravenous iloprost administration after initiation of a rewarming period during CPB in patients undergoing CABG surgery is associated with improved renal function compared with conventional treatment in well-hydrated patients. It also has a good safety profile and is generally well tolerated. Further prospective, randomized studies with iloprost or combination therapies are necessary.
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